Inventiva (BATS-CHIXE:IVAP) - Aandelenkoers, Nieuws & Analyse

IVAP Overzicht aandelen

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.

Over het bedrijf

IVAP fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 47.21% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Inventiva S.A. Concurrenten

Bioventix

AIM:BVXP

UK£193.1m

Tissue Regenix Group

AIM:TRX

UK£38.5m

Avacta Group

AIM:AVCT

UK£217.0m

Oxford Biomedica

LSE:OXB

UK£416.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Inventiva
Historische aandelenkoersen
Huidige aandelenkoers	€2.49
52 Week Hoogtepunt	€5.12
52 Week Laag	€2.49
Bèta	1.03
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-79.76%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	IVAP	GB Biotechs	GB Markt
7D	0%	1.2%	1.1%
1Y	n/a	-13.5%	11.5%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe IVAP presteerde ten opzichte van de UK Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe IVAP presteerde ten opzichte van de UK markt.

Prijsvolatiliteit

Is IVAP's price volatile compared to industry and market?
IVAP volatility
IVAP Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.5%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.3%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: IVAP heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van IVAP in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2011	111	Frederic Cren	www.inventivapharma.com

Inventiva S.A. Samenvatting

Hoe verhouden de winst en inkomsten van Inventiva zich tot de beurswaarde?
IVAP fundamentele statistieken
Marktkapitalisatie	€157.63m
Inkomsten(TTM)	-€54.27m
Inkomsten(TTM)	€18.81m

8.4x

P/S-verhouding

-2.9x

Koers/Winstverhouding

Is IVAP overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IVAP resultatenrekening (TTM)
Inkomsten	€18.81m
Kosten van inkomsten	€995.00k
Brutowinst	€17.82m
Overige uitgaven	€72.09m
Inkomsten	-€54.27m

Laatst gerapporteerde inkomsten

Dec 31, 2022

Volgende inkomensdatum

Sep 28, 2023

Winst per aandeel (EPS)	-1.29
Brutomarge	94.71%
Nettowinstmarge	-288.48%
Schuld/Eigen Vermogen Verhouding	87.7%

Hoe presteerde IVAP op de lange termijn?

Bekijk historische prestaties en vergelijking

IVAP Overzicht aandelen

Beloningen

Risicoanalyse

Inventiva S.A. Concurrenten

AIM:BVXP

UK£193.1m

AIM:TRX

UK£38.5m

AIM:AVCT

UK£217.0m

LSE:OXB

UK£416.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Recent updates

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Insufficient new directors

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Inventiva Provides Update on Development of cedirogant by AbbVie

Insufficient new directors

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Inventiva S.A., Annual General Meeting, May 19, 2022

No longer forecast to breakeven

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Forecast to breakeven in 2024

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Inventiva S.A. Samenvatting

8.4x

-2.9x

Inkomsten en omzet